

Jonathon R Campbell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8301910/publications.pdf>

Version: 2024-02-01

52
papers

2,042
citations

394286

19
h-index

265120

42
g-index

54
all docs

54
docs citations

54
times ranked

4150
citing authors

#	ARTICLE	IF	CITATIONS
1	Scaling up investigation and treatment of household contacts of tuberculosis patients in Brazil: a cost-effectiveness and budget impact analysis. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100166.	1.5	5
2	High-dose rifamycins in the treatment of TB: a systematic review and meta-analysis. <i>Thorax</i> , 2022, 77, 1210-1218.	2.7	4
3	Chapter 4: Diagnosis of tuberculosis infection. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2022, 6, 49-65.	0.2	3
4	Safety of prolonged treatment with bedaquiline in programmatic conditions. <i>ERJ Open Research</i> , 2022, 8, 00685-2021.	1.1	5
5	Prevalence, acceptability, and cost of routine screening for pulmonary tuberculosis among pregnant women in Cotonou, Benin. <i>PLoS ONE</i> , 2022, 17, e0264206.	1.1	9
6	Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2022, 75, 2201-2210.	2.9	5
7	Systematic on-site testing for SARS-CoV-2 infection among asymptomatic essential workers in Montr�al, Canada: a prospective observational and cost-assessment study. <i>CMAJ Open</i> , 2022, 10, E409-E419.	1.1	2
8	Adequacy of Serial Self-performed SARS-CoV-2 Rapid Antigen Detection Testing for Longitudinal Mass Screening in the Workplace. <i>JAMA Network Open</i> , 2022, 5, e2210559.	2.8	18
9	Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1042-1051.	4.6	28
10	Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness. <i>PLoS Medicine</i> , 2022, 19, e1004032.	3.9	6
11	Occupational stress in industry setting in Benin 2019: A cross-sectional study. <i>PLoS ONE</i> , 2022, 17, e0269498.	1.1	0
12	How Well Does TSTin3D Predict Risk of Active Tuberculosis in the Canadian Immigrant Population? An External Validation Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e3486-e3495.	2.9	3
13	Build back better: Advances in tuberculosis research in Canada & globally in 2020. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2021, 5, 121-124.	0.2	0
14	The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs. <i>Annals of Internal Medicine</i> , 2021, 174, 501-510.	2.0	160
15	The Role of Tuberculosis Screening Among Migrants to Low-Incidence Settings in (Not) Achieving Elimination. <i>American Journal of Epidemiology</i> , 2021, , .	1.6	1
16	The latent tuberculosis cascade-of-care among people living with HIV: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2021, 18, e1003703.	3.9	21
17	Tuberculosis preventive treatment in people living with HIV��Is the glass half empty or half full?. <i>PLoS Medicine</i> , 2021, 18, e1003702.	3.9	4
18	Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 713-722.	2.5	22

#	ARTICLE	IF	CITATIONS
19	Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis. PLoS Medicine, 2021, 18, e1003712.	3.9	19
20	Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. PLoS Medicine, 2021, 18, e1003738.	3.9	18
21	What makes a score a winner?. Lancet Infectious Diseases, The, 2020, 20, 10-11.	4.6	0
22	Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infectious Diseases, The, 2020, 20, 318-329.	4.6	37
23	Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. European Respiratory Journal, 2020, 55, 1901467.	3.1	55
24	Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings. Annals of Internal Medicine, 2020, 173, 169-178.	2.0	20
25	Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Lancet, The, 2020, 396, 402-411.	6.3	49
26	Active testing of groups at increased risk of acquiring SARS-CoV-2 in Canada: costs and human resource needs. Cmaj, 2020, 192, E1146-E1155.	0.9	30
27	Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. Clinical Infectious Diseases, 2020, 73, e3545-e3554.	2.9	19
28	Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine, the, 2020, 8, 383-394.	5.2	155
29	No time to waste: preventing tuberculosis in children. Lancet, The, 2020, 395, 924-926.	6.3	2
30	Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ, The, 2020, 370, m2516.	3.0	673
31	Changes in treatment for multidrug-resistant tuberculosis according to national income. European Respiratory Journal, 2020, 56, 2001394.	3.1	4
32	Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ, The, 2020, 368, m549.	3.0	58
33	Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0241536.	1.1	250
34	Title is missing!. , 2020, 15, e0241536.		0
35	Title is missing!. , 2020, 15, e0241536.		0
36	Title is missing!. , 2020, 15, e0241536.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0241536.		0
38	Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries. PLoS Medicine, 2019, 16, e1002824.	3.9	27
39	The mTST â€“ An mHealth approach for training and quality assurance of tuberculin skin test administration and reading. PLoS ONE, 2019, 14, e0215240.	1.1	9
40	Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries. Emerging Infectious Diseases, 2019, 25, 661-671.	2.0	19
41	Estimated Impact of World Health Organization Latent Tuberculosis Screening Guidelines in a Region With a Low Tuberculosis Incidence: Retrospective Cohort Study. Clinical Infectious Diseases, 2019, 69, 2101-2108.	2.9	26
42	Predicting tuberculosis relapse in patients treated with the standard 6-month regimen: an individual patient data meta-analysis. Thorax, 2019, 74, 291-297.	2.7	41
43	Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis. American Journal of Kidney Diseases, 2019, 73, 39-50.	2.1	11
44	Demographic predictors of active tuberculosis in people migrating to British Columbia, Canada: a retrospective cohort study. Cmaj, 2018, 190, E209-E216.	0.9	24
45	Testing the External Validity of a Discrete Choice Experiment Method: An Application to Latent Tuberculosis Infection Treatment. Value in Health, 2017, 20, 969-975.	0.1	22
46	Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis. Clinical Infectious Diseases, 2017, 64, 1211-1220.	2.9	25
47	Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study. BMJ Open, 2017, 7, e015108.	0.8	20
48	Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada. PLoS ONE, 2017, 12, e0186778.	1.1	15
49	Predicting tuberculosis risk in the foreign-born population of British Columbia, Canada: study protocol for a retrospective population-based cohort study. BMJ Open, 2016, 6, e013488.	0.8	15
50	A Systematic Review on TST and IGRA Tests Used for Diagnosis of LTBI in Immigrants. Molecular Diagnosis and Therapy, 2015, 19, 9-24.	1.6	50
51	A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection. Applied Health Economics and Health Policy, 2015, 13, 325-340.	1.0	21
52	Latent Tuberculosis Infection Screening in Immigrants to Low-Incidence Countries: A Meta-Analysis. Molecular Diagnosis and Therapy, 2015, 19, 107-117.	1.6	30